Abstract:DrugGPT presents a ligand design strategy based on the autoregressive model, GPT, focusing on chemical space exploration and the discovery of ligands for specific proteins. Deep learning language models have shown significant potential in various domains including protein design and biomedical text analysis, providing strong support for the proposition of DrugGPT. In this study, we employ the DrugGPT model to learn a substantial amount of protein-ligand binding data, aiming to discover novel molecules that can bind with specific proteins. This strategy not only significantly improves the efficiency of ligand design but also offers a swift and effective avenue for the drug development process, bringing new possibilities to the pharmaceutical domain.In our research, we particularly optimized and trained the GPT-2 model to better adapt to the requirements of drug design. Given the characteristics of proteins and ligands, we redesigned the tokenizer using the BPE algorithm, abandoned the original tokenizer, and trained the GPT-2 model from scratch. This improvement enables DrugGPT to more accurately capture and understand the structural information and chemical rules of drug molecules. It also enhances its comprehension of binding information between proteins and ligands, thereby generating potentially active drug candidate molecules.Theoretically, DrugGPT has significant advantages. During the model training process, DrugGPT aims to maximize the conditional probability and employs the back-propagation algorithm for training, making the training process more stable and avoiding the Mode Collapse problem that may occur in Generative Adversarial Networks in drug design. Furthermore, the design philosophy of DrugGPT endows it with strong generalization capabilities, giving it the potential to adapt to different tasks.In conclusion, DrugGPT provides a forward-thinking and practical new approach to ligand design. By optimizing the tokenizer and retraining the GPT-2 model, the ligand design process becomes more direct and efficient. This not only reflects the theoretical advantages of DrugGPT but also reveals its potential applications in the drug development process, thereby opening new perspectives and possibilities in the pharmaceutical field.### Competing Interest StatementS.H., Y.X., Y.L., C.G., X.S. and X.W. have filed a patent application (202310711607.X) relating to the autoregressive model-based drug design method in the name of the First Affiliated Hospital of Xi'an Jiaotong University School of Medicine.

Target-specific design of drug-like PPI inhibitors via hot-spot-guided generative deep learning

De novo molecular design with deep molecular generative models for PPI inhibitors

State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors

Prospective de novo drug design with deep interactome learning

Accelerating De Novo Drug Design against Novel Proteins Using Deep Learning

Interface-aware molecular generative framework for protein-protein interaction modulators

Protein-protein interface analysis and hot spots identification for chemical ligand design.

Structure-based <i>de novo</i> drug design using 3D deep generative models

DrugGPT: A GPT-based Strategy for Designing Potential Ligands Targeting Specific Proteins

Generating and screening de novo compounds against given targets using ultrafast deep learning models as core components

Learning to design drug-like molecules in three-dimensional space using deep generative models

Benchmark Study Based on 2P2I(DB) to Gain Insights into the Discovery of Small-Molecule PPI Inhibitors

Deep generative model for drug design from protein target sequence

Electron-density informed effective and reliable de novo molecular design and lead optimization with ED2Mol

TD-GPT: Target Protein-Specific Drug Molecule Generation GPT

De Novo Structure-Based Drug Design Using Deep Learning

Hotspot Identification and Drug Design of Protein-Protein Interaction Modulators Using the Fragment Molecular Orbital Method

Mining for Potent Inhibitors through Artificial Intelligence and Physics: A Unified Methodology for Ligand Based and Structure Based Drug Design

Hotspot-Driven Peptide Design via Multi-Fragment Autoregressive Extension

De Novo Design of Hsp70 Inhibitors with Objective Reinforced Generative Adversarial Networks (ORGAN) and Docking

MolAICal: a Soft Tool for 3D Drug Design of Protein Targets by Artificial Intelligence and Classical Algorithm